{"id":"bydureon","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute nephropathy","Acute vomiting","Alcoholism","Calculus in biliary tract","Chronic renal failure syndrome","Dehydration","Gastroparesis","Hypertensive disorder","Hypoglycemic disorder","Impaired renal function disorder","Pancreatitis","Severe diarrhea","Transplant of kidney"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL414357","moleculeType":"Protein","molecularWeight":"4186.64"},"aliases":["long-acting exenatide","exenatide","Exenatide"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Glucagon-like peptide 1 receptor, Glucagon-like peptide 1 receptor"},"_scrapedAt":"2026-03-28T00:26:29.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Type 2 Diabetes Mellitus Treatment Adjunct","diseaseId":"type-2-diabetes-mellitus-treatment-adjunct","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Pancreatic Cancer","enrollment":24000},{"nctId":"NCT06252623","phase":"PHASE1","title":"Exenatide For Reducing the Reinforcing Effects of Cocaine","status":"WITHDRAWN","sponsor":"Christopher D. Verrico","startDate":"2024-08-01","conditions":"Cocaine Use Disorder","enrollment":""},{"nctId":"NCT05356104","phase":"PHASE2","title":"GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-05-25","conditions":"Cerebral Small Vessel Disease","enrollment":110},{"nctId":"NCT02251431","phase":"PHASE3","title":"Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction","enrollment":57},{"nctId":"NCT04897802","phase":"PHASE4","title":"Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-09-13","conditions":"Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism","enrollment":42},{"nctId":"NCT07347080","phase":"EARLY_PHASE1","title":"A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2026-01-13","conditions":"T2DM","enrollment":9},{"nctId":"NCT07340437","phase":"","title":"Clinical Study of 18F-Exendin-4 in Insulinoma","status":"COMPLETED","sponsor":"Sichuan Provincial People's Hospital","startDate":"2023-02-01","conditions":"Insulinoma","enrollment":20},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05482789","phase":"PHASE4","title":"Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes","status":"RECRUITING","sponsor":"Maisa N. Feghali, MD","startDate":"2023-04-12","conditions":"Gestational Diabetes","enrollment":13},{"nctId":"NCT04520490","phase":"PHASE3","title":"Brain Activation and Satiety in Children 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2021-01-28","conditions":"Childhood Obesity","enrollment":63},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT05670379","phase":"PHASE1","title":"Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant","status":"COMPLETED","sponsor":"Vivani Medical, Inc","startDate":"2024-12-20","conditions":"Overweight and Obesity, Type2diabetes","enrollment":24},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06254014","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT06256419","phase":"NA","title":"Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-01-01","conditions":"Type 2 Diabetes Mellitus, Susceptibility, Genetic","enrollment":300},{"nctId":"NCT06257966","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-17","conditions":"Type2 Diabetes Mellitus","enrollment":600},{"nctId":"NCT05762744","phase":"PHASE1","title":"Pharmacogenomics of GLP1 Receptor Agonists","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2016-06-01","conditions":"Type 2 Diabetes","enrollment":63},{"nctId":"NCT04431713","phase":"PHASE2","title":"Exenatide Once-weekly as a Treatment for Multiple System Atrophy","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-16","conditions":"Multiple System Atrophy","enrollment":50},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06888167","phase":"NA","title":"Food (poly)phenol Metabotypes and Beta-cell Mass and Function.","status":"RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2024-10-14","conditions":"Healthy Volunteer","enrollment":40},{"nctId":"NCT05662189","phase":"NA","title":"Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus","status":"RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2022-03-15","conditions":"Type1diabetes, Type2diabetes, Pre Diabetes","enrollment":70},{"nctId":"NCT06725693","phase":"","title":"Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease","status":"RECRUITING","sponsor":"Tianjin Medical University","startDate":"2019-02-01","conditions":"GLP1-R-related Disease, Tumor, Insulinoma","enrollment":500},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT04154072","phase":"PHASE2","title":"A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2020-02-27","conditions":"Parkinson Disease","enrollment":255},{"nctId":"NCT04307797","phase":"PHASE4","title":"Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2022-01-18","conditions":"Type 2 Diabetes, Obesity","enrollment":10},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT02673931","phase":"NA","title":"GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Coronary Disease, Shock, Cardiogenic, Renal Failure","enrollment":1400},{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02157974","phase":"PHASE2, PHASE3","title":"Liver and Fat Regulation in Overweight Adolescent Girls","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity","enrollment":92},{"nctId":"NCT03923114","phase":"NA","title":"Imaging Pituitary ActiVation by Exendin","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-05-23","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT04909333","phase":"NA","title":"Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-29","conditions":"Endogenous Hyperinsulinism","enrollment":29},{"nctId":"NCT05347147","phase":"PHASE3","title":"A Trial to Determine the Efficacy and Safety of Presendin in IIH","status":"TERMINATED","sponsor":"Invex Therapeutics Ltd.","startDate":"2022-11-18","conditions":"Idiopathic Intracranial Hypertension","enrollment":14},{"nctId":"NCT03029351","phase":"PHASE4","title":"GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"University at Buffalo","startDate":"2017-01-10","conditions":"Type2 Diabetes, Kidney Diseases","enrollment":15},{"nctId":"NCT03835013","phase":"NA","title":"Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2019-02-11","conditions":"Cardiovascular Diseases","enrollment":26},{"nctId":"NCT02962492","phase":"NA","title":"An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2016-11-01","conditions":"Evaluate Ketogenic Stress","enrollment":70},{"nctId":"NCT05136287","phase":"","title":"SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.","status":"COMPLETED","sponsor":"Jose Seijas Amigo","startDate":"2022-02-01","conditions":"Weight Loss, Diabetes Mellitus, Type 2, Quality of Life","enrollment":140},{"nctId":"NCT03182296","phase":"NA","title":"Visualizing Beta Cells in Patients With a History of Gestational Diabetes","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-11-10","conditions":"Gestational Diabetes","enrollment":24},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT04232969","phase":"PHASE3","title":"Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease","status":"UNKNOWN","sponsor":"University College, London","startDate":"2020-01-20","conditions":"Parkinson's Disease","enrollment":194},{"nctId":"NCT04615910","phase":"PHASE2","title":"A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-07-01","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT03182192","phase":"PHASE1","title":"GLP1R-imaging in Hypoglycemia","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-04-01","conditions":"Hypoglycemia","enrollment":12},{"nctId":"NCT05418907","phase":"","title":"Exendin PET/CT for Imaging of Paragangliomas","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-06-01","conditions":"Paraganglioma","enrollment":10},{"nctId":"NCT03151005","phase":"PHASE4","title":"The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2017-07-01","conditions":"Polycystic Ovary Syndrome (PCOS), Overweight, Obesity","enrollment":70},{"nctId":"NCT04979611","phase":"PHASE1","title":"The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2020-08-01","conditions":"Insulinoma","enrollment":60},{"nctId":"NCT04504396","phase":"PHASE3","title":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-06-23","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":620},{"nctId":"NCT04504370","phase":"PHASE3","title":"Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-04-27","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":273},{"nctId":"NCT03331289","phase":"PHASE4","title":"Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-02-28","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT02981069","phase":"PHASE4","title":"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT03889496","phase":"NA","title":"Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2015-11-16","conditions":"Diabetes Mellitus","enrollment":12},{"nctId":"NCT01364584","phase":"NA","title":"Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-10","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT01511393","phase":"","title":"An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2012-01","conditions":"Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma","enrollment":6750},{"nctId":"NCT01416649","phase":"","title":"Impact of Exenatide on Sleep Duration","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-02-01","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT02621489","phase":"PHASE4","title":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-12","conditions":"Atherosclerosis, Diabetes, Restenosis","enrollment":38},{"nctId":"NCT05622123","phase":"PHASE2","title":"BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-02-23","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT02829502","phase":"PHASE2","title":"The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke","status":"UNKNOWN","sponsor":"Christina Kruuse","startDate":"2016-08","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT02302976","phase":"PHASE1","title":"GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-11","conditions":"Cocaine Dependence","enrollment":13},{"nctId":"NCT03961256","phase":"PHASE2","title":"Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-05-09","conditions":"Pre Diabetes","enrollment":9},{"nctId":"NCT05034783","phase":"EARLY_PHASE1","title":"[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"Insulinoma","enrollment":20},{"nctId":"NCT01154933","phase":"PHASE2","title":"Exeantide in Type 2 Diabetes on Insulin","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT03456687","phase":"PHASE1","title":"Effects of Exenatide on Motor Function and the Brain","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-06-05","conditions":"Parkinson's Disease","enrollment":5},{"nctId":"NCT04305002","phase":"PHASE2","title":"Exenatide Treatment in Parkinson's Disease","status":"UNKNOWN","sponsor":"Center for Neurology, Stockholm","startDate":"2020-01-21","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT04941521","phase":"PHASE1, PHASE2","title":"Exenatide for Treating Cocaine Use Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-06-24","conditions":"Cocaine Use Disorder","enrollment":3},{"nctId":"NCT03182231","phase":"PHASE1, PHASE2","title":"GLP1-imaging Before and After Bariatric Surgery","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-10-07","conditions":"Diabetes Mellitus, Type 2, Bariatric Surgery Candidate","enrollment":12},{"nctId":"NCT00775684","phase":"NA","title":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":"Pre-diabetes, Type 2 Diabetes","enrollment":47},{"nctId":"NCT02794402","phase":"PHASE2","title":"Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2015-09","conditions":"Obesity","enrollment":44},{"nctId":"NCT02664441","phase":"PHASE3","title":"Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2016-03","conditions":"Hypothalamic Obesity","enrollment":42},{"nctId":"NCT03350191","phase":"PHASE1","title":"A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-20","conditions":"Type 2 Diabetes Mellitus","enrollment":13},{"nctId":"NCT03007329","phase":"PHASE4","title":"Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-08","conditions":"Steatosis, Liver, Type2 Diabetes","enrollment":34},{"nctId":"NCT04969627","phase":"PHASE4","title":"Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.","status":"COMPLETED","sponsor":"Bing He","startDate":"2021-01-04","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT05328843","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2022-05-01","conditions":"Type2Diabetes","enrollment":24},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT01302327","phase":"NA","title":"GLP Analogs for Diabetes in Wolfram Syndrome Patients","status":"WITHDRAWN","sponsor":"Hadassah Medical Organization","startDate":"2011-03-01","conditions":"Diabetes Mellitus Associated With Genetic Syndrome, Wolfram Syndrome","enrollment":""},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT03645408","phase":"PHASE1","title":"The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-05-02","conditions":"Alcohol Use Disorder","enrollment":8},{"nctId":"NCT00882050","phase":"PHASE1, PHASE2","title":"Intravenous Exenatide (Byetta) During Surgery","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2009-03","conditions":"Euglycemia, Hypoglycemia, Hyperglycemia","enrollment":104},{"nctId":"NCT02417142","phase":"PHASE4","title":"Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2014-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":70},{"nctId":"NCT02496611","phase":"PHASE2","title":"Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2015-12","conditions":"Severe Obesity","enrollment":100},{"nctId":"NCT01554618","phase":"PHASE3","title":"Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12-02","conditions":"Children and Adolescent With Type 2 Diabetes","enrollment":84},{"nctId":"NCT03287076","phase":"PHASE2","title":"Trial of EXenatide in Acute Ischaemic Stroke","status":"UNKNOWN","sponsor":"Neuroscience Trials Australia","startDate":"2017-11-23","conditions":"Acute Ischemic Stroke","enrollment":350},{"nctId":"NCT03970044","phase":"PHASE4","title":"Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.","status":"COMPLETED","sponsor":"Consano Clinical Research, LLC","startDate":"2019-07-02","conditions":"Diabetes Mellitus, Type 2","enrollment":67},{"nctId":"NCT02847403","phase":"PHASE3","title":"Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2016-02","conditions":"Dysglycemia, Cognitive Deficit","enrollment":40},{"nctId":"NCT01269034","phase":"PHASE4","title":"New Onset Type 1 Diabetes: Role of Exenatide","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-12","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT01590433","phase":"PHASE4","title":"Weight Loss With Exenatide Treatment","status":"COMPLETED","sponsor":"Jody Dushay","startDate":"2012-03","conditions":"Obesity","enrollment":249},{"nctId":"NCT03189953","phase":"PHASE1, PHASE2","title":"68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-04","conditions":"Insulinoma","enrollment":56},{"nctId":"NCT03361098","phase":"PHASE4","title":"DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2017-09-18","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":65},{"nctId":"NCT03232112","phase":"PHASE2","title":"Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2017-08-07","conditions":"Alcohol Dependence, in Remission, Addiction, Alcohol","enrollment":152},{"nctId":"NCT03167411","phase":"PHASE1","title":"Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-05-24","conditions":"Type2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02119819","phase":"PHASE2","title":"A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT02685852","phase":"PHASE1","title":"Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-02","conditions":"Hyperinsulinemic Hypoglycemia","enrollment":11},{"nctId":"NCT04269642","phase":"PHASE2","title":"SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Peptron, Inc.","startDate":"2020-03-19","conditions":"Early Parkinson's Disease","enrollment":99},{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":45,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Bydureon","genericName":"Bydureon","companyName":"Phoenix VA Health Care System","companyId":"phoenix-va-health-care-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":10,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}